HC Wainwright Reaffirms “Buy” Rating for Legend Biotech (NASDAQ:LEGN)

HC Wainwright restated their buy rating on shares of Legend Biotech (NASDAQ:LEGN) in a report issued on Wednesday, Benzinga reports. The firm currently has a $73.00 price target on the stock.

LEGN has been the subject of several other reports. BMO Capital Markets reaffirmed an outperform rating and set a $90.00 price objective on shares of Legend Biotech in a report on Wednesday, July 3rd. Royal Bank of Canada restated an outperform rating and set a $86.00 price target on shares of Legend Biotech in a report on Monday, August 12th. TD Cowen dropped their price objective on Legend Biotech from $71.00 to $67.00 and set a buy rating on the stock in a research note on Monday, July 15th. Piper Sandler restated an overweight rating and set a $90.00 target price on shares of Legend Biotech in a research note on Monday, June 17th. Finally, Scotiabank lifted their price target on Legend Biotech from $70.00 to $76.00 and gave the stock a sector outperform rating in a research report on Monday, August 12th. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $81.78.

Legend Biotech Trading Up 1.5 %

Shares of NASDAQ:LEGN opened at $57.55 on Wednesday. The company has a current ratio of 5.66, a quick ratio of 5.57 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $10.49 billion, a PE ratio of -44.27 and a beta of 0.11. Legend Biotech has a 1 year low of $38.60 and a 1 year high of $72.38. The firm has a fifty day moving average price of $53.52 and a 200 day moving average price of $52.43.

Legend Biotech (NASDAQ:LEGN) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49. The company had revenue of $186.50 million during the quarter, compared to analysts’ expectations of $125.25 million. Legend Biotech had a negative return on equity of 27.91% and a negative net margin of 135.92%. The business’s quarterly revenue was up 154.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.27) earnings per share. Analysts expect that Legend Biotech will post -1.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Legend Biotech

Several institutional investors and hedge funds have recently bought and sold shares of LEGN. Quarry LP acquired a new stake in shares of Legend Biotech during the 4th quarter valued at about $45,000. Blue Trust Inc. lifted its stake in Legend Biotech by 10,075.0% during the second quarter. Blue Trust Inc. now owns 814 shares of the company’s stock worth $36,000 after purchasing an additional 806 shares during the period. American International Group Inc. boosted its holdings in Legend Biotech by 50.0% during the first quarter. American International Group Inc. now owns 900 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares in the last quarter. AM Squared Ltd bought a new stake in shares of Legend Biotech in the 2nd quarter valued at approximately $71,000. Finally, Barometer Capital Management Inc. acquired a new position in shares of Legend Biotech in the 4th quarter worth approximately $120,000. Institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).